RE:Bayer looking for a "mid-size M&A transaction" in oncology" The deal would likely come with a later-stage drug, Bayer’s oncology chief Christine Roth said. The right deal would also fit in Bayer’s focus tumor types and potentially within its three pillars of treatment modalities, Roth added.
Roth agreed that $5 billion to $10 billion would be a good value estimate for a midsize M&A transaction. But she also said she’s not “putting a ring fence around the dollar value.”
ONCY's pelareorep falls within Bayer's three pillars of treatment modalities, namely precision molecular oncology, next-generation immuno-oncology medicines and radioligand therapies as Bayer's top priorities.
Consequently ONCY's pelareorep platform technology value of between US$10 -US$15 Billion falls within Big Pharma's 'sweet spot' of US$5 Billion to US$25 Billion.